Day: January 26, 2026

Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology’s most challenging and valuable solid tumor targets, CEACAM5 TAMPA and LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced the filing of a new U.S. provisional patent application (No. 63/958,508) covering its second pipeline candidate, AKTX-102, an ADC directed against CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated but historically difficult-to-drug oncology target. CEACAM5 is expressed in 80–90%...

Maris‑Tech payload to fly aboard LizzieSat‑4 as hardware testing and platform integration commence ahead of planned launch later this year Rehovot, Israel; Cape Canaveral, FL, Jan. 26, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech”), a global leader in video and artificial intelligence (“AI”)- based edge computing technology, and Sidus Space (NASDAQ: SIDU) (“Sidus”), an innovative space and defense technology company, today announced the achievement of an integration milestone, as Maris‑Tech’s advanced payload is scheduled to fly aboard Sidus’ LizzieSat‑4 (LS4) mission, scheduled for launch later this year. This milestone marks the transition from planning to active integration, as Sidus and Maris‑Tech prepare to initiate testing of Maris‑Tech’s payload hardware next week. Upon completion of initial...

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution Earth Observation (“EO”) data, today announced that it has entered into a securities purchase agreement with a single institutional investment manager for the purchase and sale of 7,399,578 shares of Class A common stock at a purchase price of $4.73 per share in a registered direct offering. The gross proceeds to the Company from this offering are expected to be approximately $35 million, before deducting offering expenses. The offering is expected to close on January 27, 2026, subject to satisfaction of customary closing conditions. All of the shares issued in the offering are to be sold by the Company. Titan Partners, a division of American Capital Partners, is acting as lead placement agent for the offering. Craig-Hallum...

Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices NEW YORK and DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) — Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Platinum Dermatology Partners as the launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Platinum will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs. “This partnership with Obagi makes sense for us. They’re taking a different approach to product development, and we...

ENCINO, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the appointment of Sardar Abubakr, FCCA, as Chief Financial Officer, effective January 20, 2026. Mr. Abubakr will be based in Dubai, UAE. Roger K. Almond, the Company’s current Chief Financial Officer, will remain with NETSOL as Chief Accounting Officer, responsible for NETSOL’s global accounting operations and the preparation of its Forms 10-Q and Form 10-K filings. Mr. Abubakr brings more than two decades of international leadership experience across Europe and Asia, spanning finance, strategy, digital transformation, M&A and operations. Most recently, he served as Vice President of...

Fatality at Coringa Mine Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, regrets to announce an accident occurred resulting in a fatality at its Coringa underground operation on 25 January 2026. The accident was related to mining activity at a production face. No other personnel were injured in the incident. The Company has notified the relevant authorities, including the police, and are providing all necessary assistance for the enquiries into the incident. The involvement of the Brazilian authorities means that investigations into the circumstances of the accident remain ongoing. Production in the area of the incident is expected to be resumed within a few days once the authorities have completed their enquiries, but mining operations are otherwise...

EMERYVILLE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) — Grocery Outlet Holding Corp. (NASDAQ: GO) (“Grocery Outlet” or the “Company”), a high-growth, extreme value retailer of quality, name-brand consumables and fresh products, today announced that it raised enough funds to provide two million meals* to people facing hunger through its holiday campaign with Feeding America®, the nation’s largest hunger-relief organization. The initiative, which ran from mid-November through December 31, was part of Grocery Outlet’s ongoing commitment to fight hunger and support the local communities it operates in. During the campaign, customers were invited to donate at checkout, and store operators were able to choose which local food bank or community organization they wished to support. Grocery Outlet also matched a portion...

Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. “Our year is off to a strong start and the initiation...

The Vista West Community Park by LGI HomesThe new park at Vista West features a pickleball and basketball courts, a splashpad, playground, zip line, soccer field, baseball backstop, dog park, shaded gazebo with picnic tables and barbecue grills, and scenic walking trails.FORT WORTH, Texas, Jan. 26, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) is excited to announce the opening of a brand-new community park at Vista West, a growing residential neighborhood in Fort Worth, Texas. Spanning 13.5 acres, the park was thoughtfully designed to enhance daily life for residents by offering inviting outdoor spaces for recreation, relaxation, and connection. Located at the heart of the community, the park serves as a central gathering place where residents of all ages can enjoy a wide range of amenities. Features include...